Nanobiotix (NASDAQ:NBTX) shares rose 11.6% on Thursday after the biotech firm reported promising preliminary findings from a Phase 1 trial evaluating JNJ-1900 (NBTXR3) in patients with esophageal cancer.
The late-stage clinical company said the treatment was well-tolerated and that injections were feasible in 13 patients with locally advanced esophageal adenocarcinoma. The study demonstrated an 85% disease control rate and a 69% objective response rate, including six complete and three partial responses.
Data were presented at the 2025 Annual Meeting of the American Society for Radiation Oncology, covering cohorts 1 and 2 of the dose escalation phase. The trial examines JNJ-1900 in combination with either photon or proton chemoradiation, followed by surgery when medically appropriate.
“These early results support our hypothesis that intratumoral injection of JNJ-1900 (NBTXR3) in combination with chemoradiation is both technically feasible and generally well-tolerated in patients with locally advanced esophageal adenocarcinoma,” said Steven Lin, MD, PhD, Professor of Radiation Oncology at MD Anderson and Principal Investigator of the study.
The recommended Phase 2 dose for JNJ-1900 with photon chemoradiation was determined to be 33% of gross tumor volume. Among the six patients who underwent surgery after treatment, two achieved a pathological complete response, while four experienced a major pathological response.
Recruitment for the first dose-escalation cohort has concluded, with five more patients being enrolled in cohort 2. The trial will subsequently expand to include 12 additional patients for the dose-expansion phase.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.